Gather verified email addresses & phone numbers directly from LinkedIn
202M+
Contacts
44M+
Companies
57M+
Emails
9M+
Phone numbers
Operations Specialist, CMO
Professional Email
sta****@adctherapeutics.com
Personal Email
****@****.com
Work Phone
(908) 546*****
Mobile
(908) 546*****
Local Location
United States
HQ Location
lausanne, vaud, switzerland
Website
http://www.adctherapeutics.com
Industry
research
Designation
Operations Specialist, CMO
Birthday
-
HQ Location
lausanne, vaud, switzerland
Industry
biotechnology research
Employees
312
Specialties

Install the Orion chrome extension from the Web Store. Sign up using your email address.

The Extension will sync with your LinkedIn from where you can discover in-depth Prospects' profiles, company information and Find Similar details.

Get detailed insights of Prospects Company Profile, Email ID, Phone Number, Location or Similar Designation and much more.
1
1
Number of Companies Worked For
Number of Job Titles
Stacey Baccaro is currently employed at ADC Therapeutics. Stacey is an experienced professional working at ADC Therapeutics as the Operations Specialist, CMO. Staceys phone number is (908) 546***** and email is sta****@adctherapeutics.com to get more information install Orion extension.
Stacey Baccaro is currently employed at ADC Therapeutics.
At present, Stacey Baccaro is serving as the Operations Specialist, CMO.
The professional email used by Stacey Baccaro is sta****@adctherapeutics.com.
Stacey Baccaro's professional contact number is (908) 546*****.
Franck Silva are some of the colleagues working with Stacey Baccaro.
Elizabeth Diaz, Sonu Babu, Karen Leavitt, Tommy Roberts are some of the other counterparts holding the similar designation in other organizations like Stacey Baccaro.
Stacey Baccaro has worked for ADC Therapeuticsfalse so far.
According to the ADC Therapeutics Summary, ADC Therapeutics is a commercial-stage global pioneer in the field of antibody drug conjugates (ADCs). Our goal is to be a leading ADC company that transforms the lives of those impacted by cancer. To achieve this, we are focused on unlocking the potential value of our robust ADC portfolio across two pillars of growth: hematology and solid tumors. We are a pioneer in the ADC field with specialized end-to-end capabilities unique to ADCs including a validated technology platform, a growing next-generation research & development toolbox and a proven track record that includes an approved and marketed product. We aim to expand our portfolio and accelerate the development of our pipeline through targeted investments and in collaboration with strategic partners. In this way, we plan to pursue multiple targets in parallel, enabling us to prioritize and ensure disciplined capital allocation strategy while advancing the most promising candidates in both hematology and solid tumors. Our CD19-directed ADC ZYNLONTA® (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. Founded in 2011, ADC Therapeutics is based in Lausanne, Switzerland, with operations in London and New Jersey. Our highly skilled global team is committed to confronting cancer with the full potential of our science and transforming the treatment paradigm for patients with cancer. For more information, please visit https://www.adctherapeutics.com/..
The company is headquartered at Lausanne, Vaud, Switzerland.
Stacey Baccaro is Operations Specialist, CMO at ADC Therapeutics.
Stacey Baccaro is currently residing in United States.
Stacey Baccaro is currently working with the research industry.
Nearly 312 is the total headcount of the company.